Highland Therapeutics has announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, will host a poster presentation highlighting Phase III clinical data at the upcoming American Psychiatric Association (APA) 168th Annual Meeting in Toronto, Canada.
“The APA meeting is one of the most well attended psychiatric medical conferences; attracting physicians from around the world. We are excited to be sharing clinical data we have generated to date with the medical community at this prestigious event,” said Dr Randy Sallee, Ironshore’s Chief Medical Officer. “We will be participating at all of the major US psychiatry conferences and expect to be active in 2015 with respect to publishing clinical data and market research findings in peer-reviewed medical journals.”
Ironshore’s formulations are designed and developed to provide clinically meaningful control of ADHD symptoms throughout the day
Ironshore’s Mary Ann McDonnell will present data from a Phase III, 6-Week, open-label, dose optimization study of HLD200 in children with attention-deficit hyperactivity disorder (ADHD). The poster session will take place on Monday, 18 May 2015, at 2:00pm EDT.
Commenting on HLD-200, Dr McDonnell said, “Stimulants have been the cornerstone of ADHD pharmacologic treatment for decades and physicians continue to confidently prescribe methylphenidate and amphetamine as first-line therapy for the majority of their child and adolescent patients. However, despite their effectiveness, a substantial unmet medical need persists, as many families struggle with inadequately controlled ADHD symptoms and the related functional impairments during the morning routine. Existing long-acting stimulant therapies cannot adequately address this “gap” in coverage since they are dosed in the morning and take time before significant clinical effect is observed. Ironshore’s formulations were specifically designed and developed to provide clinically meaningful control of ADHD symptoms during the morning routine and throughout the day.”
